Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aimmune Therap (AIMT)

Aimmune Therap (AIMT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Aimmune to Present New Clinical Data at AAAAI Annual Meeting

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced it will present new data...

AIMT : 25.65 (-1.42%)
Is the Options Market Predicting a Spike in Aimmune (AIMT) Stock?

Investors need to pay close attention to Aimmune (AIMT) stock based on the movements in the options market lately.

AIMT : 25.65 (-1.42%)
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Operational Highlights

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that it will host a conference...

AIMT : 25.65 (-1.42%)
What's in Store for Aimmune (AIMT) This Earnings Season?

Aimmune (AIMT) is likely to provide an update on Palforzia's launch plans during Q4 investors' call. The drug gets an approval in January 2020 for the treatment of peanut allergy.

IMMU : 16.44 (-7.25%)
SAGE : 64.45 (-4.01%)
CLVS : 7.99 (-19.46%)
AIMT : 25.65 (-1.42%)
SmarTrend Watching for Potential Rebound in Shares of Aimmune Therapeu After 2.08% Loss

Aimmune Therapeu (NASDAQ:AIMT) traded in a range yesterday that spanned from a low of $27.55 to a high of $28.39. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of...

AIMT : 25.65 (-1.42%)
IM Therapeutics Announces Appointment of Dr. Stephen Dilly to Board of Directors

ImmunoMolecular Therapeutics, Inc. ("IM Therapeutics"), a clinical stage company developing personalized therapies for autoimmune disease, announced today that Dr. Stephen Dilly has joined its Board of...

AIMT : 25.65 (-1.42%)
CHIR : 17.50 (-0.14%)
Biotech Stock Roundup: Earnings Updates From VRTX, AMGN, GILD; AIMT Gains FDA Nod

Many biotech bigwigs came out with their fourth-quarter numbers in the past week.

GILD : 70.10 (-3.84%)
BIIB : 324.11 (-0.57%)
VRTX : 230.00 (-2.96%)
AIMT : 25.65 (-1.42%)
REGN : 442.35 (+3.99%)
UTHR : 112.86 (-2.16%)
Aimmune Therapeutics Announces Additional $200 Million Equity Investment by Nestle Health Science

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that Nestle Health Science...

AIMT : 25.65 (-1.42%)
Aimmune Licenses Exclusive Worldwide Rights to Xencor's XmAb(R)7195 for the Development of Next-Generation Food Allergy Treatments

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, announced it has granted an exclusive...

AIMT : 25.65 (-1.42%)
XNCR : 32.09 (-3.69%)
Watch for Aimmune Therapeu to Potentially Rebound After Falling 8.33% Yesterday

Aimmune Therapeu (NASDAQ:AIMT) traded in a range yesterday that spanned from a low of $29.80 to a high of $32.92. Yesterday, the shares fell 8.3%, which took the trading range below the 3-day low of...

AIMT : 25.65 (-1.42%)
Shares of Radius Health In Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (RDUS , AKBA , AIMT , ARDX , TGTX )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

AIMT : 25.65 (-1.42%)
AKBA : 8.90 (-10.91%)
RDUS : 17.90 (-6.14%)
Aimmune's Palforzia Wins FDA Approval for Peanut Allergy

Aimmune's (AIMT) Palforzia is the first medicine to receive an FDA nod for treating patients with peanut allergy. Shares rise in pre-market trading.

AIMT : 25.65 (-1.42%)
XENE : 14.50 (-5.66%)
DNLI : 22.08 (-2.69%)
KALA : 6.12 (-3.47%)
Aimmune Therapeu (AIMT)

SmarTrend identified a Downtrend for Aimmune Therapeu (NASDAQ:AIMT) on September 11th, 2019 at $24.73. In approximately 5 months, Aimmune Therapeu has returned 25.56% as of today's recent price of $31.05....

AIMT : 25.65 (-1.42%)
FDA Approves Aimmune's PALFORZIA(TM) as First Treatment for Peanut Allergy

--Company to Host Conference Call Today at 5:30 p.m. ET

AIMT : 25.65 (-1.42%)
Aimmune Therapeu Set to Possibly Rebound After Yesterday's Selloff of 4.94%

Aimmune Therapeu (NASDAQ:AIMT) traded in a range yesterday that spanned from a low of $30.21 to a high of $31.98. Yesterday, the shares fell 4.9%, which took the trading range below the 3-day low of...

AIMT : 25.65 (-1.42%)
Uptrend Call Working As Aimmune Therapeu Stock Rises 34.1% (AIMT)

SmarTrend identified an Uptrend for Aimmune Therapeu (NASDAQ:AIMT) on September 11th, 2019 at $24.73. In approximately 4 months, Aimmune Therapeu has returned 34.09% as of today's recent price of $33.16....

AIMT : 25.65 (-1.42%)
Watch for Aimmune Therapeu to Potentially Rebound After Falling 1.40% Yesterday

Aimmune Therapeu (NASDAQ:AIMT) traded in a range yesterday that spanned from a low of $33.51 to a high of $35.09. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of...

AIMT : 25.65 (-1.42%)
Aimmune Therapeu Has Returned 45.2% Since SmarTrend Recommendation (AIMT)

SmarTrend identified an Uptrend for Aimmune Therapeu (NASDAQ:AIMT) on September 11th, 2019 at $24.73. In approximately 4 months, Aimmune Therapeu has returned 45.25% as of today's recent price of $35.92....

AIMT : 25.65 (-1.42%)
SmarTrend Watching for Potential Rebound in Shares of Aimmune Therapeu After 2.86% Loss

Aimmune Therapeu (NASDAQ:AIMT) traded in a range yesterday that spanned from a low of $30.32 to a high of $31.73. Yesterday, the shares fell 2.9%, which took the trading range below the 3-day low of...

AIMT : 25.65 (-1.42%)
Is the Options Market Predicting a Spike in Aimmune Therapeutics (AIMT) Stock?

Investors need to pay close attention to Aimmune Therapeutics (AIMT) stock based on the movements in the options market lately.

AIMT : 25.65 (-1.42%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS -1.74 , SEDG -2.63 , THC -3.44 , TER -2.25 , LITE -2.20
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar